SCHEMBL16234694

SCHEMBL16234694

CC(=O)N[C@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMT2 O60551 1/20 0.53
NMT1 P30419 1/20 0.53
FURIN P09958 8/20 0.48
PCSK6 P29122 1/20 0.48
SIRT6 Q8N6T7 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
F2 P00734 1/20 0.47
F10 P00742 1/20 0.47
HPN P05981 1/20 0.47
HGFAC Q04756 1/20 0.47
ST14 Q9Y5Y6 1/20 0.47
TLR2 O60603 1/20 0.46
SIRT5 Q9NXA8 1/20 0.44
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16259323 1.00 NMT2 (0.53) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL16234712 1.00 NMT2 (0.53) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL16234715 1.00 NMT2 (0.53) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL16259360 1.00 NMT2 (0.53) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL16259340 1.00 NMT2 (0.53) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL16234693 1.00 NMT2 (0.53) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL16507920 0.95 FURIN (0.51) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL20965523 0.95 SIRT6 (0.52) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL20965281 0.91 FURIN (0.48) NMT2NMT1FURINPCSK6SIRT6
SCHEMBL20951745 0.89 FURIN (0.52) NMT2NMT1FURINPCSK6SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353149-B2 Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity SOUTHERN RESEARCH INSTITUTE (US) 2016-05-31 US disclosed
US-9353149-B2 Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity SOUTHERN RESEARCH INSTITUTE (US) 2016-05-31 US disclosed
US-20140336115-A1 Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity SOUTHERN RESEARCH INSTITUTE (US) 2014-11-13 US disclosed
US-20140336115-A1 Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity SOUTHERN RESEARCH INSTITUTE (US) 2014-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336115-A1 Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity TGFB1, TGFB2, TGFBR1 NMT2 789/4885NMT1 714/4885FURIN 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.